Patents Assigned to FRONTIER BIO-DRUG DEVELOPMENT LIMITED
  • Patent number: 10273461
    Abstract: Hepatitis C virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic DLK-1+ stem cells (hADSC) freshly isolated from HCV-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture. Furthermore, naive hADSC isolated from HCV (?) individuals support complete replication of clinical isolates in vitro, and the infection is donor-nonspecific for cells and cross-genotypic for viruses. Viral infection/replication is mediated through CD81, LDL-R, SR-B1, EGFR, Apolipoprotein E, occludin, claudin-1, NPC1L1 and diacylglycerol acetyltransferase-1, and can be inhibited by anti-viral drugs.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: April 30, 2019
    Assignee: FRONTIER BIO-DRUG DEVELOPMENT LIMITED
    Inventor: Chen-Lung Lin